Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifaximin

FDA-approved product (tablet, oral), marketed as Rifaximin, Xifaxan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rifaximin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diarrhea
  • Hepatic failure
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Other antibiotics for topical use
FDA pharmacologic class
Rifamycin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC A07AA11; WHO ATC D06AX11; FDA class Rifamycin Antibacterial

Repurposing investigation

Rifaximin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA93.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli70.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis87.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rifaximin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifaximin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • G-CSF in Decompensated Cirrhosis: an Open Label Trial

    NCT03415698 · start 2016-07

    Registered record
    Registry ID
    NCT03415698
    Conditions
    Cirrhosis, Liver
    Interventions
    G-CSF; Standard Medical Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2016-07
    Completion
    2018-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver
    InterventionG-CSF; Standard Medical Therapy
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Treating Bacterial Overgrowth in Parkinson's Disease

    NCT02470780 · start 2015-12

    Registered record
    Registry ID
    NCT02470780
    Conditions
    Parkinson's Disease; Small Intestinal Bacterial Overgrowth
    Interventions
    Rifaximin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2015-12
    Completion
    2017-08
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Small Intestinal Bacterial Overgrowth
    InterventionRifaximin; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease

    NCT02620007 · start 2015-12

    Registered record
    Registry ID
    NCT02620007
    Conditions
    Crohn Disease; Adherent-invasive E. Coli
    Interventions
    Ciprofloxacin; Rifaximin; Ciprofloxacin Placebo; Rifaximin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-12
    Completion
    2022-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn Disease; Adherent-invasive E. Coli
    InterventionCiprofloxacin; Rifaximin; Ciprofloxacin Placebo; Rifaximin Placebo
    PhasePhase 2
    Registry statusTerminated

  • Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

    NCT02498301 · start 2015-11-10

    Registered record
    Registry ID
    NCT02498301
    Conditions
    Travelers' Diarrhea; Functional Bowel Disorders; Reactive Arthritis
    Interventions
    Rifaximin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11-10
    Completion
    2019-12-31
    Enrolment
    449

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTravelers' Diarrhea; Functional Bowel Disorders; Reactive Arthritis
    InterventionRifaximin; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices

    NCT02508623 · start 2015-07

    Registered record
    Registry ID
    NCT02508623
    Conditions
    Liver Cirrhosis; Portal Hypertension
    Interventions
    Rifaximin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-07
    Completion
    2017-07
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Portal Hypertension
    InterventionRifaximin; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Fecal Microbial Transplant in Pediatric Crohn's Disease

    NCT02272868 · start 2015-01

    Registered record
    Registry ID
    NCT02272868
    Conditions
    Crohn's Disease
    Interventions
    Fecal Microbial transplant; Normal Saline; rifaximin+omeprazole+miralax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2016-10-01
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionFecal Microbial transplant; Normal Saline; rifaximin+omeprazole+miralax
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.

    NCT02321371 · start 2014-10-19

    Registered record
    Registry ID
    NCT02321371
    Conditions
    Acute-On-Chronic Liver Failure
    Interventions
    Lactulose + Rifaximin; Lactulose
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-10-19
    Completion
    2016-01-31
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute-On-Chronic Liver Failure
    InterventionLactulose + Rifaximin; Lactulose
    PhaseNot applicable
    Registry statusCompleted

  • Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients

    NCT02011841 · start 2014-01

    Registered record
    Registry ID
    NCT02011841
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Rifaximin; Ciprofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2014-01
    Completion
    2015-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionRifaximin; Ciprofloxacin
    PhasePhase 3
    Registry statusWithdrawn

  • Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

    NCT02120196 · start 2014-01

    Registered record
    Registry ID
    NCT02120196
    Conditions
    Spontaneous Bacterial Peritonitis; Ascites; Liver Cirrhosis
    Interventions
    Rifaximin; Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-01
    Completion
    2023-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis; Ascites; Liver Cirrhosis
    InterventionRifaximin; Norfloxacin
    PhasePhase 3
    Registry statusUnknown

  • To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism

    NCT02265484 · start 2013-11

    Registered record
    Registry ID
    NCT02265484
    Conditions
    Cirrhosis Related Parkinsonism
    Interventions
    Lactulose+Rifaximin +Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-11
    Completion
    2015-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis Related Parkinsonism
    InterventionLactulose+Rifaximin +Bromocriptine
    PhaseNot applicable
    Registry statusCompleted

  • Rifaximin Predicts the Complications of Decompensated Cirrhosis

    NCT02074280 · start 2013-10

    Registered record
    Registry ID
    NCT02074280
    Conditions
    Cirrhosis
    Interventions
    rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-10
    Completion
    2014-12
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis
    Interventionrifaximin
    PhasePhase 4
    Registry statusUnknown

  • Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome

    NCT01803724 · start 2013-05

    Registered record
    Registry ID
    NCT01803724
    Conditions
    Irritable Bowel Syndrome
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2013-05
    Completion
    2014-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Quality of Life and Nutritional Improvements in Cirrhotic Patients

    NCT01842113 · start 2013-04

    Registered record
    Registry ID
    NCT01842113
    Conditions
    Liver Cirrhosis; Hepatic Encephalopathy; Portal Hypertension
    Interventions
    Rifaximin; Lactulose; Lactulose Placebo; Rifaximin Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2013-04
    Completion
    Not recorded
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis; Hepatic Encephalopathy; Portal Hypertension
    InterventionRifaximin; Lactulose; Lactulose Placebo; Rifaximin Placebo
    PhasePhase 4
    Registry statusTerminated

  • Role of Methane in Glycemic Control

    NCT01638429 · start 2012-04

    Registered record
    Registry ID
    NCT01638429
    Conditions
    Diabetes; Obesity
    Interventions
    Neomycin; Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2014-04
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; Obesity
    InterventionNeomycin; Rifaximin
    PhaseEarly phase 1
    Registry statusCompleted

  • A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

    NCT01542541 · start 2011-07

    Registered record
    Registry ID
    NCT01542541
    Conditions
    Intestinal FDG Uptake
    Interventions
    Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-07
    Completion
    2012-10
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal FDG Uptake
    InterventionRifaximin
    PhaseNot applicable
    Registry statusCompleted